Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis | Zendy

Glenn W. Kaatz | Zendy; Susan M. Seo | Zendy; Jeffrey R. Aeschlimann | Zendy; Heather H. Houlihan | Zendy; Renée-Claude Mercier | Zendy; Michael J. Rybak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis

Author(s) -

Glenn W. Kaatz,

Susan M. Seo,

Jeffrey R. Aeschlimann,

Heather H. Houlihan,

Renée-Claude Mercier,

Michael J. Rybak

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.4.981

Subject(s) - vancomycin , bacteremia , staphylococcus aureus , endocarditis , methicillin resistant staphylococcus aureus , glycopeptide , antibiotics , microbiology and biotechnology , medicine , staphylococcal infections , micrococcaceae , in vivo , antibacterial agent , biology , bacteria , genetics

The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistantStaphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research